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Abstract
Background: Erythropoietin receptor (EPOR) is a functional membrane-bound cytokine receptor. Erythropoietin
(EPO) represents an important hematopoietic factor for production, maturation and differentiation of erythroid
progenitors. In non-hematopoietic tissue, EPO/EPOR signalization could also play cytoprotective and anti-
apoptotic role. Several studies identified pro-stimulating EPO/EPOR effects in tumor cells; however, numerous
studies opposed this fact due to the usage of unspecific EPOR antibodies and thus potential absence or very
low levels of EPOR in tumor cells. It seems that this problem is more complex and therefore we have
decided to focus on EPOR expression at several levels such as the role of methylation in the regulation of
EPOR expression, identification of possible EPOR transcripts and the presence of EPOR protein in selected
tumor cells.
Methods: Methylation status was analysed by bisulfite conversion reaction, PCR and sequencing. The
expression of EPOR was monitored by quantitative RT-PCR and western blot analysis.
Results: In this study we investigated the methylation status of exon 1 of EPOR gene in selected human
cancer cell lines. Our results indicated that CpGs methylation in exon 1 do not play a significant role in the
regulation of EPOR transcription. However, methylation status of EPOR exon 1 was cell type dependent. We
also observed the existence of two EPOR splice variants in human ovarian adenocarcinoma cell line - A2780
and confirmed the expression of EPOR protein in these cells using specific A82 anti-EPOR antibody.
Conclusion: We outlined the methylation status of all selected cancer cell lines in exon 1 of EPOR gene and
these results could benefit future investigations. Moreover, A82 antibody confirmed our previous results
demonstrating the presence of functional EPOR in human ovarian adenocarcinoma A2780 cells.
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Background
The erythropoietin (EPO) is a glycoprotein produced by
the kidney depending on the amount of oxygen [1].
During oxygen deprivation, heat shock protein 70 stimu-
lates the production of EPO, which is the main regulator
of erythropoiesis. EPO is involved in the formation, mat-
uration and differentiation of erythroid precursors after
binding to EPO specific membrane receptor (EPOR) [2].
Since the observed positive stimulating effect of EPO/
EPOR on the haematopoiesis, the production of recom-
binant human EPO (rhEPO) was initiated by pharma-
ceutical companies and subsequently it was approved for
anaemia treatment. Human rhEPO is also used as alter-
native to transfusion of blood in cancer patients where
anaemia is accompanying sign of chemotherapy [3].
Human DNA is enriched by methylated cytosine resi-
dues (CpG; cytosine-phospho-guanosine dinucleotide)
that have major functions in the epigenetic regulation of
genes, cellular differentiation and are essential for nor-
mal development and genomic integrity [4]. Many hu-
man cancer cell lines harbour distinct variations in
promoter CpG methylation patterns, which profoundly
affect gene expression [5, 6] . Therefore, DNA methyla-
tion could serve as an epigenetic biomarker of human
tumors. Methylation of the transcriptional initiation/
elongation region is very important for transcriptional
suppression. Methylation of the first exon is also tightly
linked to transcriptional silencing of genes [7]. In
addition, it was established that methylation of leading
exon blocks gene transcription, whereas methylation of
next downstream exons has been positively correlated
with transcription initiated from upstream region. It was
also postulated that first exon methylation could regulate
the selection of alternative starts [8].
Splicing variants of EPOR were detected in the variety of
cell lines and tumors [9]. Alternative splicing of EPOR re-
sults in three different EPOR transcripts with different
hematopoietic function: full length EPOR (EPOR-F),
truncated EPOR (EPOR-T) and soluble EPOR (EPOR-S).
Introns between the seventh and the eighth exons are
spliced to form EPOR-T with loss of part of the intracellular
domain. EPOR-T was observed in normal hematopoietic
tissue with apoptotic effects attenuating role in erythropoi-
esis and also in leukemic cells with proapoptotic and
anti-apoptotic responses [10].
There are many studies demonstrating that EPO/
EPOR signalization in cancer cells can: induce cell pro-
liferation [11–14], change the sensitivity to chemothera-
peutics [11, 12], induce angiogenesis [15] and/or tumor
neovascularization [16]. However, there are studies
where no growth response to EPO treatment was ob-
served [17–19]. Furthermore, in some studies using a
sensitive A82 anti-EPOR antibody no EPOR was de-
tected or it was detected only in low levels in many
different cancer cell lines [20, 21]. These facts lead to
additional questions; the most important of which is,
what could be the reason for such variations in out-
comes from different studies. Could these differences be
attributed to methodological procedures, sources of cell
lines or usage of the different (possibly non-specific)
antibodies? In this regard, we adopted the opinion of
Patterson [22], that the differences in studies are mainly
the consequence of the distribution of unspecific pri-
mary EPOR antibodies. As a result, not only the pres-
ence of EPOR protein, but also its amount or its size
differs in the observed cell lines [23].
In our study, we focused on the monitoring of CpG
sites around the first exon (+ 1/+ 125) of EPOR gene
(NG_021395.1) in various cancer cell lines because of
large EPOR promoter homogeneity with other genes and
very high homogeneity and tandem repetitions in EPOR
promoter itself. We decided to search for potential cor-
relation between the methylation status in this region
and its transcriptional activity as well as EPOR spliced
variants. EPOR protein level in all monitored cell lines
was evaluated using three different antibodies.
Methods
Cell culture conditions
The ovarian adenocarcinoma A2780, lung adenocarcinoma
A549, colorectal adenocarcinoma HT-29, hepatocellular
carcinoma HEP-G2, mammary adenocarcinoma MCF-7
and mammary carcinoma T47D cell lines were obtained
from the American Tissue Culture Collection (ATCC; VA,
USA). The acute myeloid leukemia UT-7 cells and renal
carcinoma 769P cell lines were purchased from Leibniz -
Institut DSMZ, Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (DSMZ; Germany). The parental
non-metastatic benign tumor-derived rat mammary epithe-
lial cells RAMA 37 and its derived stably transformed cell
subclone RAMA 37–28 [24], transfected with pcDNA3.1
expression vector contained wild type human EPOR gene
[using 1.0mg/ml geneticin selection of modified cells [25]]
were obtained as a gift from University of Ljubljana, Faculty
of Medicine. All cell lines were grown in RPMI-1640
medium supplemented with L-glutamine (Gibco; Thermo
Fisher Scientific, Inc., MA, USA), 10% fetal bovine serum
(Gibco; Thermo Fisher Scientific, Inc.) and antibiotic and
antimycotic solution (100U/ml penicillin - 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin B; Thermo
Fisher Scientific, Inc.). The medium for UT-7 cell line was
enriched with 1 U/ml rhEPO (40,000 U/ml; EPREX®; Jans-
sen Biologics B.V., Netherlands) and the medium for T47D
cells with 100U/ ml Insulin (1: 1,000; Humulin M3
Cartridge; Lilly France S.A.S., France). We used standard
cell culture conditions with 37 °C and 5% CO2/95% air and
ZF Coulter counter (Beckman Coulter, Inc., CA, USA) for
determination of cells number. Additionally, cell viability
Fecková et al. BMC Genetics            (2019) 20:1 Page 2 of 9
using 0.15% eosin staining and the light microscopy was
analysed.
Methylation analysis
DNA isolation
Genomic DNA (gDNA) from cell lines was isolated ac-
cording to the protocol by GeneJET Genomic DNA
Purification Kit (K0721; Thermo Fisher Scientific, Inc.).
DNA samples were quantified by spectrophotometer
BioSpec-nano (Shimadzu Scientific Instruments, MD,
USA) and the integrity was analysed by horizontal 1.2%
agarose gel electrophoresis stained with GelRed Nucleic
Acid (Biotium, Inc., USA).
Bisulfite conversion reaction
Bisulfite modification was performed by MethylCode™
Bisulfite Conversion Kit (MECOV-50; Invitrogen, CA,
USA). After the conversion, 500 ng (200 ng for positive
control) of DNA was diluted in 10 μl of Elution buffer.
Acquisition of fully methylated genomic DNA
For higher yield of fully methylated DNA (positive con-
trol), the gDNA (1 μg) was subjected to restriction by
BamHI endonuclease (40 U / μl; 10,798,975,001; Roche
Applied Science, Germany) with 10 X SuRE/Cut Buffer
in total volume of 50 μl at 37 °C / overnight. Inactivation
of BamHI was performed for 15 min at 65 °C. The cleav-
age of DNA samples was then verified by horizontal 1%
agarose gel electrophoresis. The enzyme and buffer com-
pounds were removed by ethanol precipitation. Briefly,
DNA was mixed with 0.1 volumes of 3M Sodium acet-
ate (pH 5.2, final concentration 0.3M) and 3 volumes of
ice cold 100% ethanol and incubated for 1 h at − 80 °C.
After precipitation, DNA pellets were centrifuged
(13,000 x g / 30 min / 4 °C), washed twice with ice cold
75% ethanol, followed by resuspension of air-dried DNA
in nuclease free water and measured concentration. Fully
methylated DNA was prepared by using CpG methyl-
transferase (M.SssI; New England Biolabs, Inc., UK). For
adequate amount of DNA, we performed methyltrans-
feration in triplicate (one tube / 100 ng of DNA). The
100 ng of DNA was protected by 0.04 U / μl of M.SssI,
160 μMS-adenosylmethionine (SAM) and 1 X NEBuffer
2 in total volume 20 μl until 1 h at 37 °C. For enzyme in-
activation and removing S-adenosyl-L-homocysteine
(SAH, inhibiting product from SAM), we performed
ethanol precipitation. After that, the same DNA was
protected by M.SssI and ethanol-purified again. Fully
methylated DNA (< residual 200 ng) was subjected to bi-
sulfite conversion as described above.
Primer design and PCR conditions
The EPOR promoter and gene sequence (NG_021395.1) was
analysed by MethPrimer software (http://www.urogene.org/
methprimer/) to identify CpG sites. After this analyse, we de-
signed primers for sequence around first exon in normal
gDNA (forward primer 5’-CTG GTC GGG AAG GGC
CTG GTC AGC T-3′, reverse primer 5’-CAC GCA GCT
CAT CCT TAC CTT TGC TCT CGA ACT TGG-3′) and
bisulfite modificated DNA (forward primer 5′-ATT TGT
TAT TTA GAG GCG TTT GGT CGG GAA GG-3′, re-
verse primer 5’-CCA CAC GCA ACT CAT CCT TAC CTT
TAC TCT C-3′). PCRs with normal unmethylated gDNA
(negative control), bisulfite modificated DNA and fully meth-
ylated bisulfite modificated DNA (positive control) were per-
formed in duplicates by C1000 Touch Thermal Cycler
(Bio-Rad Laboratories, Inc.), respectively. A 50 μl reaction
volume contained 0.025U / μl of AmpliTaq Gold 360 DNA
polymerase, 10 X AmpliTaq Gold 360 Buffer, 1.5mMMgCl2,
2.6 μl of GC Enhancer or 1.3 μl of GC Enhancer (bisulfite
modificated DNA and positive control), 0.5 μM forward and
reverse primer and 83 ng of gDNA. The reaction conditions
were: denaturation 10min at 95 °C, 30 cycles, consisting of
denaturation for 30 s at 95 °C, annealing for 30 s at 68.5 °C
or 62 °C (bisulfite modificated DNA and positive control)
and extension for 20 s at 72 °C, following by final extension
for 7min at 72 °C. PCR products were then subjected to
electrophoresis in 1.5% agarose gel stained with GelRed Nu-
cleic Acid (Biotium, Inc.).
Sequencing
The PCR products were purified using ExoSAP-ITTM
PCR Product CleanUp Reagent (Thermo Fischer Scien-
tific, Inc.) for 15 min at 37 °C followed by incubation for
15 min at 85 °C. After agarose gel electrophoresis control
stained with GelRed Nucleic Acid (Biotium, Inc.), we
performed sequencing reaction (10 μl) using sequencing
kit BigDye Terminator v1.1 (Applied Biosystems, Inc.,
CA, USA). The reaction mixtures for normal DNA
(negative control) contained 1 μl of BigDye mix (dNTPs,
ddNTPs, DNA polymerase), 1 μl of 10 μM forward pri-
mer for normal DNA, 0.5 μl of diluted PCR product and
7.5 μl of dH2O. The reaction mixtures for bisufite modi-
ficated DNA or positive control contained 2 μl of BigDye
mix, 1 μl of 10 μM forward primer for bisufite DNA, 1 μl
of PCR product and 6 μl of dH2O. The PCRs were per-
formed in Personal Thermal Cycler MJ Mini (Bio-Rad
Laboratories, Inc.). The reaction conditions were: 2 min
at 95 °C, 35 cycles, consisting of denaturation for 15 s at
95 °C, annealing for 30 s at 68.5 °C (negative control) or
62 °C (bisulfite modificated DNA and positive control)
and extension for 4 min at 60 °C, followed by final exten-
sion for 7 min at 60 °C. After that, the 10 μl of PCR
products were purified by SigmaSpin Post-Reaction
Clean-Up Columns (Sigma-Aldrich, Inc., MO, USA). For
capillary electrophoresis, we prepared a mixture of 12 μl
of Formamid (HiDi Formamide, Applied Biosystems,
USA) and 3 μl of purified PCR products in sequencing
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microplate. The samples in microplate were denatured for
3min at 95 °C and then cooled down on ice. The sequen-
cing analyses proceeded in 3500 Genetic Analyser
(Applied Biosystems, Inc.) by capillary electrophoresis
(3500 Capillary Array, Applied Biosystems, Inc.) and sepa-
rated polymer (POP-7™ Polymer for 3500/3500xL Genetic
Analysers, Applied Biosystems, Inc.). The obtained se-
quences we analysed by SnapGene Viewer (http://
www.snapgene.com) and aligned with sequences in data-
base BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
RNA isolation, reverse transcription and quantitative RT-
PCR
The RNA was isolated using TRIzol™ reagent (Gibco,
Invitrogen, NY, USA) according to the manufacturer’s
instructions. The concentration of RNA was determined
at 260 nm and purity was controlled by the ratio 260/
280 nm and 260/230 nm using spectrophotometer
BioSpec-nano (Shimadzu Scientific Instruments). The
integrity and quality of RNA was verified by horizontal
1% agarose gel electrophoresis. Then, 1 μg of RNA was
reverse transcribed using mixture of oligo(dT) and ran-
dom primers by iScript™ Advanced cDNA Synthesis Kit
for RT-qPCR (Bio-Rad Laboratories, Inc., CA, USA).
Quantitative RT-PCRs (each analysis in duplicate) were
done using CFX96 Touch Real Time PCR Detection Sys-
tem (Bio-Rad Laboratories, Inc.) in 10 μl of reaction vol-
ume containing 1 X iTaq™ Universal SYBR Green
Supermix, 0.5 μM forward and reverse primers and 1 μl
of cDNA. We used PCR conditions as it is follows: 30 s
at 95 °C, 40 cycles of denaturation 5 s at 95 °C, annealing
/ extension 45 s at 55.5 °C, 61 °C or 60 °C for EPOR-F,
EPOR-T or EPOR-S, respectively. The amplification was
followed by melting curve analysis to confirm amplifica-
tion of the desired single and specific product. EPOR-F
primers (forward primer: 5’-GCT GGA AGT TAC CCT
TGT GG-3′, reverse primer: 5’-CTC ATC CTC GTG
GTC ATC CT-3′; the amplicon length: 148 bp) were de-
signed by Trošt et al. [26], EPOR-T primers (forward pri-
mer: 5’-CTG ACG CCT AGC GAC CTG GAC C-3′,
reverse primer: 5’-GCA GTT TGG CTG CAA GAA
GCA-3′; the amplicon length: 249 bp) and EPOR-S
primers (forward primer: 5′-GGA GCC AGG GCG
AAT CAC GG -3′, reverse primer: 5′- GCC TTC AAA
CTC GCT CTC TG -3′; the amplicon length: 204 bp) by
Arcasoy et al. [9]. The expression of the tested genes
was normalized to the expression of internal reference
gene (β actin). The relative expression of EPOR and β
actin (forward primer: 5’-ACC AAC TGG GAC GAC
ATG GAG AAA ATC-3′, reverse primer: 5′-GTA GCC
GCG CTC GGT GAG GAT CTT CAT-3′; the amplicon
length: 366 bp) were obtained through the calculation of
standard curves with cDNA mixtures (diluted four-fold
times) used. The relative EPOR expression was normalized
to the expression of β actin. The results are presented as
mean ± standard deviation of three independent experi-
ments. Only samples with Ct values ≤28 were considered
for quantification (EPOR-F and EPOR-T in all tested sam-
ples). The samples with Ct values > 28 acquired the ampli-
fication product bellow the limit as UQL (under
quantification limit).
EPOR protein detection
All cell lines were washed twice with 1 X ice-cold
phosphate-buffered saline (PBS; pH 7.2–7.4), scraped into
lysis buffer [Tris-HCl (pH 7.4), 0.1% SDS, 10% glycerol and
100 X protease inhibitor cocktail (Sigma-Aldrich, Inc.)] and
incubated for 45min. Then, lysates were homogenized by
sonication on ice for 30 s at 30 V (Sonopuls HD 2070;
Bandelin electronic GmbH & Co. KG, Germany). After
sonication, lysates were centrifuged at 10,000 x g for 10
min at 4 °C and the supernatants were transferred into 1.5
ml microcentrifuge tubes and quantified according to the
Lowry protein assay protocol (Bio-Rad Laboratories, Inc.).
Lysates (100 μg or 300 μg each) were then boiled in 4 X
Laemmli Sample buffer (1,610,747; Bio-Rad Laboratories,
Inc.) for 10min, separated with 12% SDS-polyacrylamide
gel electrophoresis (PAGE) and blotted onto a polyvinyli-
dene fluoride (PVDF) membranes with transfer buffer [3.6
g Tris, 18 g glycine and 10% methanol (pH 7.4)]. The PVDF
membranes were washed for 10min with 1 X PBS (pH
7.2–7.4) or 1 X Tris-buffered saline (TBS; pH 7.2–7.4) and
blocked with 5% non-fat milk in 1 X PBS + 0.1% Tween
[1X PBST; pH 7.2–7.4 (Sigma-Aldrich, Inc.)] or 1 X TBS +
0.1% Tween (1 X TBST; pH 7.2–7.4) for 45min. Then, the
membranes were washed for 1min and incubated over-
night at 4 °C with primary anti-EPOR monoclonal anti-
bodies respectively: A82 (1: 1250; Amgen, Inc., CA, USA)
with 1% non-fat milk in 1 X TBST (pH 7.2–7.4), AF322PB
(1: 500; R&D Systems, Inc., MN, USA) and AT1931a (1:
5000; Abgent, Inc., CA, USA) with 1% non-fat milk in 1 X
PBST (pH 7.2–7.4). As loading control, we used primary
anti-ß actin antibody (8H10D10; 1: 1000; Cell Signaling
Technology, Inc., Leiden, Netherlands) in 5% non-fat milk
in 1 X TBST (pH 7.2–7.4).
Next day, the membranes were washed three times for 10
min in 1 X TBST (pH 7.2–7.4) or 1 X PBST (pH 7.2–7.4)
and incubated for 1 h with secondary horseradish peroxidase
(HRP) - conjugated antibodies: goat anti-rabbit (31,461; 1:
5000; Thermo Fisher Scientific, Inc.), rabbit anti-goat
(31,403; 1: 10,000; Thermo Fisher Scientific, Inc.) and goat
anti-mouse (31,436; 1: 10,000; Thermo Fisher Scientific, Inc.)
at room temperature (RT). The antibody reactivity was visu-
alized with Pierce ECL Western Blotting Substrate (Thermo
Fisher Scientific, Inc.). Bioluminescent signals were detected
with ChemiDoc™ XRS+ and Image Lab 3.0 software
(Bio-Rad Laboratories, Inc.) or X-ray films (Roberts Technol-
ogy Group, Inc., PA, USA).
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Results
Detection of CpG sites methylation in EPOR first exon by
dideoxy sequencing
We defined CpG sites in EPOR promoter and gene body
with MethPrimer software. Because of large EPOR pro-
moter homogeneity with other genes and very high homo-
geneity and tandem repetitions in EPOR promoter itself,
the area around first exon was chosen. We performed bi-
sulfite modification of the DNA isolated from eight hu-
man cancer cell lines. Bisulfite modification discriminates
between cytosine and methylated cytosine by bisulfite salt
conversion of cytosine to uracil while methylated cytosine
remains unchanged. After dideoxy sequencing of normal
DNA (negative control), bisulfite modified DNA (experi-
mental group) and fully methylated DNA (positive con-
trol) sequences were compared. The comparison of
bisulfite modified DNA isolated from eight human cancer
cell lines (UT-7, 769-P, A2780, A549, HT-29, HEP G2,
MCF-7, T47D) is presented in Fig. 1. EPOR positive can-
cer cell line UT-7 revealed the highest 96% methylation
profile of monitored sequence. Very high methylation was
also observed in A549 cell line (86%) and in EPOR nega-
tive cancer cell line 769P (73%). Interestingly, human
breast cancer cell lines MCF-7 and T47D demonstrated
similar high 64 and 63% methylation profile, respectively.
The medium methylation of the exon 1 of EPOR was ob-
served in A2780 cell line (50%), whereas HT-29 and and
HEP G2 cell lines showed the lowest methylation levels,
36 and 30%, respectively.
Detection of EPOR-F and EPOR-T splicing variants
Based on our finding that EPOR positive UT-7 cells did
not reveal expected strong expression, we selected a new
positive control. In this regard, RAMA 37–28 - stably
transformed cell line with wild type human EPOR gene
was used. The expression of splicing variants of EPOR
gene was normalized to ß actin expression. The relative
values are shown in Fig. 2. In addition to high expression
of variant EPOR-F in RAMA 37–28 cell line (38.65), we
also observed expression of this variant in A2780 cell
Fig. 1 The methylation status of the first exon of EPOR gene in eight human cancer cell lines. The upper figure presents the sequence of EPOR
first exon (+ 1/+ 251), the transcriptional start site (+ 1), the translation start site (+ 137), bold grey 17 CpG dinucleotides and the underlined
monitored part. The lower part of figure demonstrates the methylation status of the first exon of EPOR gene. The pie charts are depicting the
percentage of methylation, where black color represents full methylation of CpG dinucleotides and grey color represents unmethylated CpG. TSS,
transcriptional start site; CG, cytosine-guanosine dinucleotide; EPOR, erythropoietin receptor
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line (1.65). Compared to A2780 cells low expression of
EPOR-F was found also in all monitored cancer cells
(UT-7 0.38, 769P 0.05, A549 0.08, HT-29 0.64, HEP G2
0.11, MCF-7 0.26 and T47D 0.41). For details see Fig. 2a.
Interestingly, A2780 cells demonstrated higher expression
of EPOR-T (2.14) than EPOR-F splicing variant. Very low
expression of EPOR-T was also seen in other tested hu-
man cancer cell lines (UT-7 0.45, 769P 0.09, A549 0.11,
HT-29 0.20, HEP G2 0.04, MCF-7 0.24 and T47D 0.33)
(Fig. 2b).
EPOR-S mRNA transcript variant was weakly detected
in UT-7, A2780 and A549 cell lines, whereas the rest of
analysed human cancer cell lines (769P, HT-29, HEP G2,
MCF-7 and T47D) revealed only the traces of EPOR-S
mRNA. Therefore, the quantification was unreliable and
assigned to belong under quantification limit (UQL)
(data not shown).
EPOR protein detection
The controversial specificity of primary monoclonal
anti-EPOR antibodies available on the market, lead us to
test three of available antibodies (Fig. 3). Western Blot
analysis with A82 antibody (donated by Amgen, Inc.)
confirmed high expression of EPOR protein (< 59 kDa)
in RAMA 37–28 as well as A2780 cell lines, which cor-
related with high expression of EPOR gene in those cells
(Fig. 3a). A smaller amount of EPOR protein was de-
tected in UT-7 and other cell lines. The only exception
Fig. 2 The relative amount of EPOR-F (a) and EPOR-T (b) mRNA transcripts in cancer cell lines. The expression of both EPOR-F and EPOR-T were
normalized to ß actin expression. Data are presented as means ± SD of three independent experiments. EPOR-F, full length erythropoietin
receptor; EPOR-T, truncated erythropoietin receptor
Fig. 3 Western blot analysis of cell lysates using three anti-EPOR primary antibodies: A82 in size < 59 kDa (a) and AF322PB (b), AT1931a in size <
47 kDa (c). The detection of ß actin protein served as loading control (d). EPOR, erythropoietin receptor; kDa, kilo Dalton; R 37, RAMA 37; R37–28,
RAMA 37–28
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was EPOR negative 769P cell line, showing no EPOR signal.
Interestingly, in comparison with A82 antibody, AF322PB
and the AT1931a antibodies detected approximately equal
EPOR signals in all cell lines, however, the positive signal
was observed at approximately 47 kDa (Fig. 3b and c). From
these observations, we could conclude that distinct signals,
detected by AF322PB and AT1931a antibodies, could be
due to non-specificity of these two tested antibodies. For all
comparisons, the anti-ß actin antibody was used as a load-
ing control (Fig. 3d).
Discussion
Epigenetic inactivation of tumor suppressor coding and
non-coding genes in human cancer and its role in aber-
rant division, immortality, genomic instability, metastasis
and metabolic reprogramming of tumor cells have been
extensively reviewed in the paper of [27]. Based on de-
methylation of genomic DNA, resulting in upregulation
of EPOR mRNA Wallach et al. [28] hypothesized that
EPOR downregulation during brain development could
be a result of epigenetic alterations. According to the
same authors [28] there are 31 CpGs in EPOR 5′-flank-
ing region from nt − 1779 to − 606 followed by 330 bp
long CpG-free sequence. Another sequence of 19 CpGs
was found at the position − 274 nt going up to the trans-
lation start site (+ 137).
The methylation of promoter regions is well described;
however, the role of open reading frame methylation is
still unclear. In this study we decided to evaluate the
methylation status of EPOR gene in the region of first
exon. Jones [29] suggested that the position of the
methylation patterns in the transcription units could
have varying effects on the gene expression. In this re-
gard, methylation in the close vicinity of the TSS blocks
initiation of transcription. Singer et al. [30] demon-
strated on human fibroblast cell-line and primary B cells
that intragenic methylation correlates well with gene ex-
pression and that exons are more highly methylated than
their neighbouring introns. Recently, Song et al. [31]
confirmed the existence of positive correlation between
exon-level DNA methylation status and mRNA expres-
sion in the Pacific oyster of Crassostrea gigas.
The majority of our selected cancer cell lines, with the
exception of A2780 cell line, showed negative correlation
between the monitored methylation of EPOR CpG sites
and its transcription. Indeed, A2780 cell line was the
only cancer cell line, where 50% methylation rate of ob-
served CpG sites did not negatively influence the expres-
sion of EPOR. On the contrary, the expression of EPOR
was higher in A2780 compared to EPOR positive UT-7
cancer cells. Interestingly, the rate of methylation in cell
lines (A2780, HT-29, HEP G2, MCF-7, T47D) was less
intensive in the first six CpG sites than in the rest of
eleven ones (last nine CpGs are part of exon 1) which in
TSS sequence correspond to the results obtained by
Wallach et al. [28]. In contrast, the rate of methylation
in cell lines UT-7, 769P and A549 was relatively high
across all examined CpG sites. Wallach et al. [28] re-
vealed low methylation rate and a different methylation
pattern of CpGs in − 300/+ 149 fragment of EPOR com-
paring SY-SY5Y cells (fetal neuronal phenotype) to speci-
mens of human adult brain. Moreover, the methylation
in mentioned sequence did not totally reduce EPOR
transcription [28]. We have observed a similar trend, as
despite of high methylation rate some of our cells dem-
onstrated low EPOR transcription. In this regard, the
highest methylation status of our monitored sequence
(96%) found in EPOR positive UT-7 cells did not inhibit
the transcription of EPOR gene, and low concentrations
of mRNA were detected. However, in EPOR negative
769P cancer cell line, high 73% rate of methylation
inhibited the transcription of EPOR. Based on this
contradictory result, we could conclude that the methy-
lation of CpGs in exon 1 of EPOR gene does not play a
significant role in the regulation of EPOR transcription.
Nevertheless, it appeared that the methylation status of
this area in EPOR gene could be cell type dependent.
For example, human breast cancer cell lines MCF-7 and
T47D revealed similar CpG methylations in this region
of EPOR gene, which is also a feature, which differenti-
ates these cell lines from the others. In this regard, Bre-
net et al. [7] proposed that genes with the lowest
transcription levels have specific methylated regions in
the first exons. Moreover, the DNA methylation of gen-
omic regions close to TSS and first exon was strongly
associated with gene repression, and interestingly, the ef-
fects of the methylation patterns in these regions on
gene expression were different in different molecular
subtypes of breast cancer [7].
It has been suggested that the methylation of gene
bodies might even stimulate transcription elongation
and/or influence the splicing of the genes [29]. Recently,
Song et al. [31] demonstrated an association between
exon-level DNA methylation and mRNA expression in
the oyster and suggested also that the exon-level DNA
methylation might play a role in the alternative splicing
by positively affecting exon inclusion during transcrip-
tion [31].
We have evaluated mRNA levels of two transcription
forms of EPOR, EPOR-F and EPOR-T. We compared
mRNA of these two splicing variants in EPOR positive
cell lines as well as in negative control; however, we did
not observe correlation between the methylation status
of CpGs in exon 1 and the occurrence of full length or
truncated mRNA transcripts of EPOR. In comparison
with all selected cell lines, a slightly increased amount of
truncated variant of EPOR was detected in A2780 cell
line. In order to identify the correlation between
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epigenetic regulation and splicing patterns of EPOR, fur-
ther studies are needed.
To demonstrate the protein levels of EPOR gene in cell
lines we used recommended specific anti-EPOR anti-
body – A82 [23] for EPOR detection in non-erythroid
cells. The A82 antibody was optimized for flow cytome-
try as well as western blot detection and the size of the
protein detected by western blot analysis was 59 kDa.
The authors found out that the positive transcription
signals of EPOR positive control cells were proportional
to EPOR protein level with a minimal signal of EPOR
expression in negative cells [23]. In this study, we com-
pared three commercially available EPOR antibodies,
A82, AF322PB and AT1931a. Our results confirmed the
specificity of A82 antibody for the detection of EPOR
protein in EPOR positive UT-7 and EPOR overexpress-
ing RAMA 37–28 cell lines. However, AF322PB and
AT1931a antibodies did not show the desired specificity.
Surprisingly, in cell line A2780 we observed stronger ex-
pression of EPOR than in positive control cell line UT-7,
both at mRNA as well as at protein level (A82 antibody).
The discrepancy in EPOR expression in A2780, UT-7
and other cell lines might be the consequence of differ-
ent culturing (inactivated or regular serum) and/or ex-
perimental conditions [32]. In our studies, we usually
use A2780 cells descended from ATCC and we analyse
them between the passages 23–25 using standard RPMI
media and an inactivated serum (see Material and
methods section). Nevertheless, using A82 antibody we
confirmed our previous results demonstrating the pres-
ence (expression) of the functional EPOR in this particu-
lar A2780 cell line [33–35]. In addition, we outlined the
methylation status of all selected cancer cell lines in
exon 1 of EPOR gene and these results could benefit fu-
ture investigations of the significance of the methylation
in the vicinity of the first exon and its relation to the
transcriptional and/or splicing variant regulation.
Conclusion
However the methylation status of EPOR exon 1 was
cell type dependent CpGs methylation in this exon do
not play a significant role in the regulation of EPOR
transcription. We also demonstrated the existence of
two EPOR splice variants in human ovarian adenocar-
cinoma cell line - A2780 and confirmed the expres-
sion of EPOR protein in these cells using specific
A82 anti-EPOR antibody.
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